- Dell Taking Further Steps To Cut Staff and Costs
- Marvel Posts Marvel-ous Profits, Sees Modest 2009
- Consumer Bankruptcies Soar in October
- Why the US Market Rallied Even Before Vote Was Over
- Fiscal Boost Needed to Lift Economy: Fed's Fisher
- World Closely Watching US Election
- GE Open to Using Bailout Money For Lending Arm
- Factory Orders Drop More than Expected
- Global Stocks Stage Rally As US Votes for President
- Oil: Fourth Biggest One-Day Gain Ever
- Investor Fear Dropping
- Election Day Long Lines Are For—Starbucks!
- Stop Trading!: Election Day Trading
- Intrade Political Futures: Will this election make the Senate Filibuster Proof?
- Big Pharma "Healthier" For Obama With Campaign Money
- Iron Man Drives Marvel's 40 Percent Earnings Growth
- More From McCain Headquarters: Will Palin Speak? (Yes)
- Accidental Dividends?
- Magna Entertainment sees no reason for stock jump
- Sudan: 2 newspapers strike against censorship
- Boeing says 787 test flight delayed due to strike
- Recession may jeopardize 401(k) contributions
- Some companies reducing or suspending 401(k) match
- Kenexa shares plunge on profit miss, tepid outlook
- Bad investment pushes Kenneth Cole to 3Q loss
- Vivus reports nearly 80 percent drop in profit
- D.R. Horton expects $800M-$900M loss in 4Q
- Unit Corp. shares rise on 3Q profit report
Text Size 
WASHINGTON - The Food and Drug Administration approved a new drug Friday to treat patients with overactive bladder, a disorder that causes frequent, uncontrollable urination.
Toviaz, made by German manufacturer Schwarz Pharma, helps relax the bladder muscles, reducing the urge to urinate and accidental leakage. New York-based Pfizer will distribute the once-a-day pill.
Overactive bladder treatments already on the market include Allergan's pill Sanctura, and Watson Pharmaceutical's Oxytrol, which comes in a patch.
The FDA said it approved Toviaz based on the results of two studies involving more than 1,000 patients with the disorder. Both studies showed the drug reduced the number of times patients had to urinate per day, and the number of leakage accidents per day.
Side effects reported with the drug included dry mouth, constipation and dry eyes.
Shares of Pfizer Inc. added 28 cents to $18.14 in afternoon trading.
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes